Name of Resource


Triplication alpha-synuclein iPSCs (MRC Centre for Regenerative Medicine)

Name of Principal Investigator - Title


Dr

Name of Principal Investigator - First name


Tilo

Name of Principal Investigator - Last name


Kunath

Address of institution -Institution


MRC Centre for Regenerative Medicine, Univerisity of Edinburgh

Address of institution - Street address


5 Little France Drive

Address of institution - City


Edinburgh

Address of institution - Postcode


EH16 4UU

Country


United Kingdom

Website


http://www.crm.ed.ac.uk/people/tilo-kunath

Contact email


[email protected]

Summary


Human induced pluripotent stem cells (iPSCs) were established from a family with triplication of the alpha-synuclein gene. A collection of lines were derived from a female Parkinson's patient, AST, and also from her unaffected daughter, NAS. These lines were published in Devine et al, 2011 (PMID:21863007). A gene editted isogenic control line, AST23-2KO6, was created from a PD line, AST23. All the iPSC lines have been deposited into EBiSC (https://www.ebisc.org/) and are available for academic and industrial projects.

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions? (1)


Parkinson's disease & PD-related disorders

Q1b. Does your resource hold


Induced Pluripotent Stem Cells (iPSC)

Q2a. Does the resource act as a centre for access and distribution to external groups (who are not the Principal Investigators (PI) for the resource)?


Yes

Q2b. If Yes, what procedures and rules apply for access?


Access independent of collaboration with PI| International access| Access to industry

Q3a. Does your resource develop experimental models (animal/cell) for external groups?


Yes

Q3b. If YES and your resource is related to an ANIMAL model, what types of models are provided?


Q3c. If YES and your resource is related to a CELL model, what types of models are provided?


Patient derived| Gene edited

Q4a. Is this activity supported as:


A collaboration

Q4b. Do you deposit what you supply in any kind of central repository?


Yes

Disease


Species


Available to external user


Full phenotypic character


Please indicate the phenotypes


List of genotypes or other subtypes


Q5b. Cognitive function, No of models


Q5b. Cognitive function, Available to external users


Q5b. Cognitive function, Full phenotypic characterisation


Q5b. Cognitive function, Nature of phenotype


Q5b. Motor function, No of models


Q5b. Motor function, Available to external users


Q5b. Motor function, Full phenotypic characterisation


Q5b. Motor function, Nature of phenotype


Q5b. Physiological function, no of models


Q5b. Physiological function, Available to external users


Q5b. Physiological function, Full phenotypic characterisation


Q5b. Physiological function, Nature of phenotype


Q5b. Other function (please specify), no of models


Please specify other function


Q5b. Other function (please specify), Available to external users


Q5b. Other function (please specify), Full phenotypic characterisation


Q5b. Other function (please specify), Nature of phenotype


Q6. Please indicate if your resource is already linked into European or international consortia or networks?


EBiSC, European Bank of induced Stem Cells

Q7a. Is maintenance of this resource dependent on continued funding?


Yes

Q7b. If yes, when does the current funding period end?


Q7c. What is the expected lifespan of the resource (in years)?


Indefinite

Q7d. Are there other plans affecting future use that it may be useful to know?


No

Export as PDF